Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | Findings from a Phase I trial of autologous SVF therapy in ALS

Zenglin Cai • 27 Jun 2026
EAN 2026
Amyotrophic Lateral Sclerosis Neuromuscular Disorders

Zenglin Cai, PhD, Nanjing Medical University, Nanjing, China, discusses a Phase I trial (ChiCTR2400091754) exploring autologous stromal vascular fraction (SVF) therapy in amyotrophic lateral sclerosis (ALS). Dr Cai shares key findings on the efficacy and safety, demonstrating that SVF therapy is safe and effective in these patients. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Improving the diagnosis of inflammatory myopathies: signals to facilitate early recognition
1:55
Improving the diagnosis of inflammatory myopathies: signals to facilitate early recognition
Nicolas Dubuisson • 27 Jun 2026
A session at EAN 2026 on advances in the management of non-inflammatory peripheral neuropathies
1:07
A session at EAN 2026 on advances in the management of non-inflammatory peripheral neuropathies
Nicolas Dubuisson • 27 Jun 2026
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial
3:58
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial
Richard Nowak • 24 Jun 2026
One big question with Richard Nowak: what MG advance could transform care in the next 3 years?
2:07
One big question with Richard Nowak: what MG advance could transform care in the next 3 years?
Richard Nowak • 28 Jun 2026
The content of VJNeurology is intended for healthcare professionals